AS3MT, GSTO, and PNP polymorphisms: Impact on arsenic methylation and implications for disease susceptibility

Environmental Research

Volumn 132, Issue , 2014, Pages 156-167

  Antonelli, Ray ^a   Shao, Kan ^a   Thomas, David J ^b   Sams, Reeder ^c   Cowden, John ^c  

^a OAK RIDGE INSTITUTE FOR SCIENCE AND EDUCATION   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

^c U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

Arsenic; Arsenic methyltransferase; Genetic polymorphisms; Glutathione s transferase omega; Purine nucleoside phosphorylase

Indexed keywords

ARSENIC 3 METHYLTRANSFERASE; ARSENIC DERIVATIVE; ENZYME; GLUTATHIONE TRANSFERASE OMEGA; PURINE NUCLEOSIDE PHOSPHORYLASE; UNCLASSIFIED DRUG;

ARSENIC; DISEASE SEVERITY; ENZYME ACTIVITY; EPIDEMIOLOGY; GENOTYPE; HEALTH IMPACT; METABOLISM; POLYMORPHISM;

CONCENTRATION (PARAMETERS); DISEASE PREDISPOSITION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; METABOLITE; METHYLATION; PHENOTYPE; PRIORITY JOURNAL; REVIEW;

ARSENIC; ARSENIC METHYLTRANSFERASE; GENETIC POLYMORPHISMS; GLUTATHIONE-S-TRANSFERASE OMEGA; PURINE NUCLEOSIDE PHOSPHORYLASE;

ARSENIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; GLUTATHIONE TRANSFERASE; HUMANS; METHYLATION; METHYLTRANSFERASES; PURINE-NUCLEOSIDE PHOSPHORYLASE;

EID: 84899863877     PISSN: 00139351     EISSN: 10960953     Source Type: Journal    
DOI: 10.1016/j.envres.2014.03.012     Document Type: Review

References (96)

1. Agusa T., et al. Genetic polymorphisms in AS3MT and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol. Appl. Pharmacol. 2009, 236:131-141.
2. Agusa T., et al. Genetic polymorphisms in glutathione S-transferase (GST) superfamily and arsenic metabolism in residents of the Red River Delta, Vietnam. Toxicol. Appl. Pharmacol. 2010, 242:352-362.
3. Ahsan H., et al. Arsenic metabolism, genetic susceptibility, and risk of premalignant skin lesions in Bangladesh. Cancer Epidemiol. Biomark. Prev. 2007, 16:1270-1278.
4. Beebe-Dimmer J.L., et al. Genetic variation in glutathione S-transferase omega-1, arsenic methyltransferase and methylene-tetrahydrofolate reductase, arsenic exposure and bladder cancer: a case-control study. Environ. Health 2012, 11:43.
5. Centeno J.A., et al. Pathology related to chronic arsenic exposure. Environ. Health Perspect. 2002, 110(Suppl 5):S883-S886.
6. Challenger F. Biological methylation. Adv. Enzymol. Relat. Subj. Biochem. 1951, 12:429-491.
7. Chen B., et al. Mouse arsenic (+3 oxidation state) methyltransferase genotype affects metabolism and tissue dosimetry of arsenicals after arsenite administration in drinking water. Toxicol. Sci. 2011, 124:320-326.
8. Chen C.J., et al. Atherogenicity and carcinogenicity of high-arsenic artesian well water. Multiple risk factors and related malignant neoplasms of blackfoot disease. Arteriosclerosis 1988, 8:452-460.
9. Chen C.L., et al. Ingested arsenic, characteristics of well water consumption and risk of different histological types of lung cancer in northeastern Taiwan. Environ. Res. 2010, 110:455-462.
10. Chen C.L., et al. Arsenic in drinking water and risk of urinary tract cancer: a follow-up study from northeastern Taiwan. Cancer Epidemiol. Biomark. Prev. 2010, 19:101-110.
11. Chen G.Q., et al. Methylated metabolites of arsenic trioxide are more potent than arsenic trioxide as apoptotic but not differentiation inducers in leukemia and lymphoma cells. Cancer Res. 2003, 63:1853-1859.
12. Chen J.W., et al. Arsenic methylation, GSTO1 polymorphisms, and metabolic syndrome in an arseniasis endemic area of southwestern Taiwan. Chemosphere 2012, 88:432-438.
13. Chen Y.C., et al. Arsenic methylation and skin cancer risk in southwestern Taiwan. J. Occup. Environ. Med. 2003, 45:241-248.
14. Chen Y.C., et al. Arsenic methylation and bladder cancer risk in Taiwan. Cancer Causes Control 2003, 14:303-310.
15. Chiou H.Y., et al. Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan. Mutat. Res. 1997, 386:197-207.
16. Chowdhury U.K., et al. Glutathione-S-transferase-omega [MMA(V) reductase] knockout mice: enzyme and arsenic species concentrations in tissues after arsenate administration. Toxicol. Appl. Pharmacol. 2006, 216:446-457.
17. Chung C.J., et al. Polymorphisms in arsenic metabolism genes, urinary arsenic methylation profile and cancer. Cancer Causes Control 2009, 20:1653-1661.
18. Chung C.J., et al. Gene polymorphisms of glutathione S-transferase omega 1 and 2, urinary arsenic methylation profile and urothelial carcinoma. Sci. Total Environ. 2011, 409:465-470.
19. Concha G., et al. Metabolism of inorganic arsenic in children with chronic high arsenic exposure in northern Argentina. Environ. Health Perspect. 1998, 106:355-359.
20. De Chaudhuri S., et al. Genetic variants associated with arsenic susceptibility: study of purine nucleoside phosphorylase, arsenic (+3) methyltransferase, and glutathione S-transferase omega genes. Environ. Health Perspect. 2008, 116:501-505.
21. Delnomdedieu M., et al. Reduction and binding of arsenate and dimethylarsinate by glutathione: a magnetic resonance study. Chem. Biol. Interact. 1994, 90:139-155.
22. Drobna Z., et al. Environmental exposure to arsenic, AS3MT polymorphism and prevalence of diabetes in Mexico. J. Expo. Sci. Environ. Epidemiol. 2013, 23:151-155.
23. Drobna Z., et al. Disruption of the arsenic (+3 oxidation state) methyltransferase gene in the mouse alters the phenotype for methylation of arsenic and affects distribution and retention of orally administered arsenate. Chem. Res. Toxicol. 2009, 22:1713-1720.
24. Drobna Z., et al. Metabolism and toxicity of arsenic in human urothelial cells expressing rat arsenic (+3 oxidation state)-methyltransferase. Toxicol. Appl. Pharmacol. 2005, 207:147-159.
25. Drobna Z., et al. shRNA silencing of AS3MT expression minimizes arsenic methylation capacity of HepG2 cells. Chem. Res. Toxicol. 2006, 19:894-898.
26. Engstrom K., et al. Polymorphisms in arsenic(+III oxidation state) methyltransferase (AS3MT) predict gene expression of AS3MT as well as arsenic metabolism. Environ. Health Perspect. 2011, 119:182-188.
27. Engstrom K.S., et al. Efficient arsenic metabolism-the AS3MT haplotype is associated with DNA methylation and expression of multiple genes around AS3MT. PLoS One 2013, 8:e53732.
28. Escobar-Garcia D.M., et al. Association of glutathione S-transferase omega 1-1 polymorphisms (A140D and E208K) with the expression of interleukin-8 (IL-8), transforming growth factor beta (TGF-beta), and apoptotic protease-activating factor 1 (Apaf-1) in humans chronically exposed to arsenic in drinking water. Arch. Toxicol. 2012, 86:857-868.
29. Fu S., et al. Urinary arsenic metabolism in a Western Chinese population exposed to high-dose inorganic arsenic in drinking water: influence of ethnicity and genetic polymorphisms. Toxicol. Appl. Pharmacol. 2013, 274:117-123.
30. Gilbert-Diamond D., et al. Rice consumption contributes to arsenic exposure in US women. Proc. Natl. Acad. Sci. USA 2011, 108:20656-20660.
31. Gong G., O[U+05F3]Bryant S.E. Low-level arsenic exposure, AS3MT gene polymorphism and cardiovascular diseases in rural Texas counties. Environ. Res. 2012, 113:52-57.
32. Gregus Z., Nemeti B. Purine nucleoside phosphorylase as a cytosolic arsenate reductase. Toxicol. Sci. 2002, 70:13-19.
33. Hernandez A., et al. High arsenic metabolic efficiency in AS3MT287Thr allele carriers. Pharmacogenet. Genomics 2008, 18:349-355.
34. Hopenhayn-Rich C., et al. Methylation study of a population environmentally exposed to arsenic in drinking water. Environ. Health Perspect. 1996, 104:620-628.
35. Hsieh Y.C., et al. Significantly increased risk of carotid atherosclerosis with arsenic exposure and polymorphisms in arsenic metabolism genes. Environ. Res. 2011, 111:804-810.
36. Hsu L.I., et al. Genetic polymorphisms in glutathione S-transferase (GST) superfamily and risk of arsenic-induced urothelial carcinoma in residents of southwestern Taiwan. J. Biomed. Sci. 2011, 18:51.
37. Hsueh Y.M., et al. Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer. Cancer Epidemiol. Biomark. Prev. 1997, 6:589-596.
38. Huang Y.K., et al. Changes in urinary arsenic methylation profiles in a 15-year interval after cessation of arsenic ingestion in southwest Taiwan. Environ. Health Perspect. 2009, 117:1860-1866.
39. Huang Y.K., et al. Arsenic exposure, urinary arsenic speciation, and the incidence of urothelial carcinoma: a twelve-year follow-up study. Cancer Causes Control 2008, 19:829-839.
40. Huang Y.K., et al. Arsenic methylation capability and hypertension risk in subjects living in arseniasis-hyperendemic areas in southwestern Taiwan. Toxicol. Appl. Pharmacol. 2007, 218:135-142.
41. Hughes M.F., et al. Arsenic (+3 oxidation state) methyltransferase genotype affects steady-state distribution and clearance of arsenic in arsenate-treated mice. Toxicol. Appl. Pharmacol. 2010, 249:217-223.
42. IARC Iarc Working Group on the Evaluation of Carcinogenic Risks to Humans: Some Drinking-Water Disinfectants and Contaminants, Including Arsenic., IARC Monographs on the Evaluation of Carcinogenic Risks to Humans 2004, 84. International Agency for Research on Cancer, Lyon, France.
43. IARC Iarc Working Group on the Evaluation of Carcinogenic Risks to Humans: Arsenic, metals, fibres, and dusts. IARC Monogr Eval Carcinog Risks Hum. 2012, 100:11-465.
44. Kile M.L., et al. A pathway-based analysis of urinary arsenic metabolites and skin lesions. Am. J. Epidemiol. 2011, 173:778-786.
45. Knobeloch L.M., et al. Association of arsenic-contaminated drinking-water with prevalence of skin cancer in Wisconsin[U+05F3]s Fox River Valley. J. Health Popul. Nutr. 2006, 24:206-213.
46. Lamm S., et al. An epidemiologic study of arsenic-related skin disorders and skin cancer and the consumption of arsenic-contaminated well waters in Huhhot, inner Mongolia. China Hum. Ecol. Risk Assess. 2007, 13:713-746.
47. Lanssens S., Ongenae K. Dermatologic lesions and risk for cancer. Acta Clin. Belg. 2011, 66:177-185.
48. Lesseur C., et al. A case-control study of polymorphisms in xenobiotic and arsenic metabolism genes and arsenic-related bladder cancer in New Hampshire. Toxicol. Lett. 2012, 210:100-106.
49. Li X., et al. Arsenic methylation capacity and its correlation with skin lesions induced by contaminated drinking water consumption in residents of chronic arsenicosis area. Environ. Toxicol. 2011, 26:118-123.
50. Lin S., et al. A novel S-adenosyl-l-methionine:arsenic(III) methyltransferase from rat liver cytosol. J. Biol. Chem. 2002, 277:10795-10803.
51. Lindberg A.L., et al. Gender and age differences in the metabolism of inorganic arsenic in a highly exposed population in Bangladesh. Environ. Res. 2008, 106:110-120.
52. Lindberg A.L., et al. Metabolism of low-dose inorganic arsenic in a central European population: influence of sex and genetic polymorphisms. Environ. Health Perspect. 2007, 115:1081-1086.
53. Lindberg A.L., et al. The risk of arsenic induced skin lesions in Bangladeshi men and women is affected by arsenic metabolism and the age at first exposure. Toxicol. Appl. Pharmacol. 2008, 230:9-16.
54. Marahatta S.B., et al. Polymorphism of glutathione S-transferase omega gene and risk of cancer. Cancer Lett. 2006, 236:276-281.
55. Marnell L.L., et al. Polymorphisms in the human monomethylarsonic acid (MMA V) reductase/hGSTO1 gene and changes in urinary arsenic profiles. Chem. Res. Toxicol. 2003, 16:1507-1513.
56. Mass M.J., et al. Methylated trivalent arsenic species are genotoxic. Chem. Res. Toxicol. 2001, 14:355-361.
57. Maull E.A., et al. Evaluation of the association between arsenic and diabetes: a National Toxicology Program workshop review. Environ. Health Perspect. 2012, 120:1658-1670.
58. McCarty K.M., et al. Arsenic methylation, GSTT1, GSTM1, GSTP1 polymorphisms, and skin lesions. Environ. Health Perspect. 2007, 115:341-345.
59. Moon K.A., et al. Association between exposure to low to moderate arsenic levels and incident cardiovascular disease. A prospective cohort study. Ann. Intern. Med. 2013, 159:649-659.
60. Nemeti B., Gregus Z. Glutathione-dependent reduction of arsenate in human erythrocytes-a process independent of purine nucleoside phosphorylase. Toxicol. Sci. 2004, 82:419-428.
61. Nemeti B., et al. Polynucleotide phosphorylase and mitochondrial ATP synthase mediate reduction of arsenate to the more toxic arsenite by forming arsenylated analogues of ADP and ATP. Toxicol. Sci. 2010, 117:270-281.
62. Arsenic in Drinking Water 1999, NRC, The National Academies Press. Washington, D.C.
63. Paiva L., et al. Association between GSTO2 polymorphism and the urinary arsenic profile in copper industry workers. Environ. Res. 2010, 110:463-468.
64. Pierce B.L., et al. Genome-wide association study identifies chromosome 10q24.32 variants associated with arsenic metabolism and toxicity phenotypes in Bangladesh. PLoS Genet. 2012, 8:e1002522.
65. Polimanti R., et al. Lack of association between essential hypertension and GSTO1 uncommon genetic variants in Italian patients. Genet. Test Mol. Biomark. 2012, 16:615-620.
66. Pongstaporn W., et al. Polymorphism of glutathione S-transferase Omega gene: association with risk of childhood acute lymphoblastic leukemia. J. Cancer Res. Clin. Oncol. 2009, 135:673-678.
67. Pu Y.S., et al. Urinary arsenic profile affects the risk of urothelial carcinoma even at low arsenic exposure. Toxicol. Appl. Pharmacol. 2007, 218:99-106.
68. Radabaugh T.R., et al. Arsenate reductase II. Purine nucleoside phosphorylase in the presence of dihydrolipoic acid is a route for reduction of arsenate to arsenite in mammalian systems. Chem. Res. Toxicol. 2002, 15:692-698.
69. Rodrigues E.G., et al. GSTO and AS3MT genetic polymorphisms and differences in urinary arsenic concentrations among residents in Bangladesh. Biomarkers 2012, 17:240-247.
70. Sampayo-Reyes A., et al. Arsenic induces DNA damage in environmentally exposed Mexican children and adults. Influence of GSTO1 and AS3MT polymorphisms. Toxicol. Sci. 2010, 117:63-71.
71. Schlawicke Engstrom K., et al. Genetic polymorphisms influencing arsenic metabolism: evidence from Argentina. Environ. Health Perspect. 2007, 115:599-605.
72. Schlawicke Engstrom K., et al. Arsenic metabolism is influenced by polymorphisms in genes involved in one-carbon metabolism and reduction reactions. Mutat. Res. 2009, 667:4-14.
73. Silva R.G., et al. Arsenate and phosphate as nucleophiles at the transition states of human purine nucleoside phosphorylase. Biochemistry 2011, 50:2701-2709.
74. Smith A.H., Steinmaus C.M. Health effects of arsenic and chromium in drinking water: recent human findings. Annu. Rev. Public Health 2009, 30:107-122.
75. Sober A.J., Burstein J.M. Precursors to skin cancer. Cancer 1995, 75:645-650.
76. Steinmaus C., et al. Arsenic methylation and bladder cancer risk in case-control studies in Argentina and the United States. J. Occup. Environ. Med. 2006, 48:478-488.
77. Steinmaus C., et al. Individual differences in arsenic metabolism and lung cancer in a case-control study in Cordoba, Argentina. Toxicol. Appl. Pharmacol. 2010, 247:138-145.
78. Strange R.C., et al. Polymorphism in glutathione S-transferase loci as a risk factor for common cancers. Arch. Toxicol. Suppl. 1998, 20:419-428.
79. Styblo M., et al. Comparative toxicity of trivalent and pentavalent inorganic and methylated arsenicals in rat and human cells. Arch. Toxicol. 2000, 74:289-299.
80. Thomas D.J. Arsenolysis and thiol-dependent arsenate reduction. Toxicol. Sci. 2010, 117:249-252.
81. Thomas D.J., et al. Arsenic (+3 oxidation state) methyltransferase and the methylation of arsenicals. Exp. Biol. Med. (Maywood) 2007, 232:3-13.
82. Tsai S.M., et al. Mortality for certain diseases in areas with high levels of arsenic in drinking water. Arch. Environ. Health 1999, 54:186-193.
83. Tseng C.H., et al. Arsenic exposure, urinary arsenic speciation, and peripheral vascular disease in blackfoot disease-hyperendemic villages in Taiwan. Toxicol. Appl. Pharmacol. 2005, 206:299-308.
84. Tseng W.P., et al. Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan. J. Natl. Cancer Inst. 1968, 40:453-463.
85. Vahter M. Metabolism of arsenic. Environmental Effects of Arsenic 1983, 171-197. Elsevier, Oxford. B.A. Fowler (Ed.).
86. Vahter M., et al. A unique metabolism of inorganic arsenic in native Andean women. Eur. J. Pharmacol. 1995, 293:455-462.
87. Valenzuela O.L., et al. Association of AS3MT polymorphisms and the risk of premalignant arsenic skin lesions. Toxicol. Appl. Pharmacol. 2009, 239:200-207.
88. Wu M.M., et al. Effect of plasma homocysteine level and urinary monomethylarsonic acid on the risk of arsenic-associated carotid atherosclerosis. Toxicol. Appl. Pharmacol. 2006, 216:168-175.
89. Wu M.M., et al. Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am. J. Epidemiol. 1989, 130:1123-1132.
90. Xu Y., et al. Lack of association of glutathione-S-transferase omega 1(A140D) and omega 2 (N142D) gene polymorphisms with urinary arsenic profile and oxidative stress status in arsenic-exposed population. Mutat. Res. 2009, 679:44-49.
91. Yang C.Y., et al. Bladder cancer mortality reduction after installation of a tap-water supply system in an arsenious-endemic area in southwestern Taiwan. Environ. Res. 2005, 98:127-132.
92. Yang C.Y., et al. Reduction in kidney cancer mortality following installation of a tap water supply system in an arsenic-endemic area of Taiwan. Arch. Environ. Health 2004, 59:484-488.
93. Yokohira M., et al. Effect of sodium arsenite dose administered in the drinking water on the urinary bladder epithelium of female arsenic (+3 oxidation state) methyltransferase knockout mice. Toxicol. Sci. 2011, 121:257-266.
94. Yu R.C., et al. Arsenic methylation capacity and skin cancer. Cancer Epidemiol. Biomark. Prev. 2000, 9:1259-1262.
95. Yuan Y., et al. Acute myocardial infarction mortality in comparison with lung and bladder cancer mortality in arsenic-exposed region II of Chile from 1950 to 2000. Am. J. Epidemiol. 2007, 166:1381-1391.
96. Zakharyan R.A., et al. Human monomethylarsonic acid (MMA(V)) reductase is a member of the glutathione-S-transferase superfamily. Chem. Res. Toxicol. 2001, 14:1051-1057.